Narcolepsy Therapeutics Market Trends, Volume - Industry Analysis, And Outlook 2023 - 2030.

Narcolepsy Therapeutics Market is segmented By Disease Type (Daytime Extreme Sleepiness, Cataplexy, Others), By Therapeutic Type (Sodium Oxybate, Central Nervous System Stimulants, Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitor, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

Narcolepsy Therapeutics Market Overview

A report by DataM Intelligence estimates the global Narcolepsy Therapeuticsmarket to grow at a CAGR of 10.1% during the forecast period 2023- 2030. North America holds the dominant market share in recent times. The competitive rivalry intensifies with Jazz Pharmaceutical Plc, Arena Pharmaceutical, Inc., Ligand Pharmaceuticals Inc., and others operating in the market.

Narcolepsy is a rare sleep disorder associated with uncontrollable sleepiness and frequent daytime sleeping. The condition is characterized by several symptoms, including excessive daytime sleepiness (EDS), cataplexy, automatic behaviors, hallucinations, and sleep paralysis. Narcolepsy has no cure, but drug therapies and lifestyle changes can often help improve symptoms.

Narcolepsy Therapeutics Market Scope

To know more insigts Download Sample

Narcolepsy Therapeutics Market Trends

Narcolepsy therapeutics market is growing due to several factors such as the rising prevalence of narcolepsy, growing narcolepsy awareness programs, increasing research & development for new drugs and treatment for narcolepsy.

The narcolepsy affects 0.03 to 0.16% of the general population with an incidence of 1/2,000 globally. The American Academy of Sleep Medicine's International Classification of Sleep Disorders has classified two forms of narcolepsy: narcolepsy with cataplexy (also called narcolepsy type 1 (NT1)) and narcolepsy without cataplexy (also known as narcolepsy type 2 (NT2)). The NT1 is most commonly caused by a deficiency of central nervous system (CNS) hypocretin (hcrt also called orexin) in the hypothalamus. The prevalence of narcolepsy type 1 is 25 to 50 per 100,000 people and 20 to 34 per 100,000 people for narcolepsy type 2.

The robust pipeline portfolio also drives this growth of the market. There are currently few approved therapies available for narcolepsy. Some of the approved drugs for narcolepsy are Xyrem (sodium oxybate), amphetamine, Nuvigil (armodafinil), Provigil (modafinil), and methylphenidate. The majority of the drugs are also used off-label for narcolepsy, including stimulants, depressants, and antidepressants. In October 2018, the Food and Drug Administration has cleared Xyrem (sodium oxybate) oral solution to treat cataplexy and excessive daytime sleepiness in patients ages 7-17 with narcolepsy. The two highest-selling drugs are expected to be Avadel’s/ Sodium oxybate ER and Jazz Pharmaceutical’s/JZP-258, which both address some of the unmet needs in the market.

However, market growth is hindered by the adverse effects and risks associated with narcolepsy drugs and delayed diagnosis.

Narcolepsy Therapeutics Market Segmentation Analysis

On the basis of disease type, the narcolepsy therapeutics market is segmented into daytime extreme sleepiness (DES), cataplexy, and others. Among these, daytime extreme sleepiness (DES) accounted for the largest market share in 2018, due to the rising prevalence of narcolepsy and other sleep disorders. Daytime extreme sleepiness is one of the most common sleep-related patient symptoms affecting an estimated 20% of the population. Obstructive sleep apnea is a particularly significant cause of excessive daytime sleepiness. An estimated 26 to 32% of adults are at risk of or have obstructive sleep apnea, and the prevalence is expected to increase during the forecast period. About 20% of adults in the United States report a level of daytime sleepiness sufficient to interfere with daily activities, and excessive daytime sleepiness is the leading symptom of patients presenting to sleep clinics. On the other hand, the cataplexy segment is expected to grow at the fastest CAGR during the forecast period (2020-2027), as patients suffering from cataplexy tend to lose muscle control and the majority of narcolepsy patients have this symptom. Cataplexy is a common type of narcolepsy disorder, which affects nearly around 0.02% to 0.05% of the population globally.

By therapeutics type, the narcolepsy Therapeutics market is segmented into central nervous system stimulants, sodium oxybate, triTheelective serotonin reuptake inhibitors, and others. The sodium oxybate segment held the largest market share in 2018, as these drugs are highly effective to treat day by therapeutics type time extreme sleepiness and cataplexy. Sodium oxybate (Xyrem) is the sodium salt of gamma-hydroxybutyrate (GHB), a naturally occurring substance in the brain. Sodium oxybate is quite different from the other medications used to treat narcolepsy as it is a sedating liquid taken at bedtime instead of a usual pill taken during the day. Its effects last only a few hours, a second dose is taken three to four hours later. These two doses produce deep sleep through much of the night, and after several weeks of regular use, sodium oxybate usually improves daytime sleepiness and cataplexy. On the other hand, the selective serotonin reuptake inhibitor segment is expected to grow at the fastest CAGR during the forecast period (2020-2027), due to rising R&D activities for the development of these types of drugs by the major players in the market.

Narcolepsy Therapeutics Market Geographical Penetration

North America holds the dominant market share for narcolepsy therapeutics in 2018, and it is expected to maintain the growth over the forecast period, due to the factors, such as rising prevalence of narcolepsy and other sleep disorders, robust pipeline product for the treatment of narcolepsy by manufactures, and rising awareness towards this sleep disorder. In the United States, around 1 among the 2000 patients are affected by narcolepsy disorder. The prevalence in North America is around 0.07%. Thus, the growing measures in therapeutics for the diagnosis and treatment of narcolepsy lead to the growth of the market in the North American region during the forecast period (2020-2027). For instance, on August 15th, 2019, the US FDA has app north America region's growth sciences) for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy. Pitolisant is the first and only treatment approved for patients with narcolepsy that is not scheduled as a controlled substance by the US Drug Enforcement Administration. Pitolisant is expected to be commercially available to healthcare professionals and appropriate patients in the US in the fourth quarter of 2019.

Narcolepsy Therapeutics Company and Competitive Landscape

The narcolepsy therapeutics market is highly competitive with the presence of a large number of players, including Jazz Pharmaceutical plc, Arena Pharmaceutical, Inc., Ligand Pharmaceuticals Inc., Bioprojet Pharma, Novartis, Teva Pharmaceutical Industries Ltd., Shinogi Inc., Takeda Pharmaceutical Company, Addrenex Pharmaceuticals, , among others hire Plc.

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the narcolepsy therapeutics market globally. For instance,

In March 2019, Jazz Pharmaceuticals plc received the U.S. FDA approval for Sunosi™ (solriamfetol) to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

In January 2018, Glenmark Pharmaceutical entered into a license agreement with Ligand Pharmaceuticals to use the full range of OmniAb platform to discover mono multispecific antibodies.